Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium

Breast Cancer Research

Volumn 15, Issue 1, 2013, Pages

  Tarulli, Gerard A ^a   De Silva, Duvini ^b   Ho, Victor ^a   Kunasegaran, Kamini ^a   Ghosh, Kakaly ^a   Tan, Bryan C ^a   Bulavin, Dmitry V ^c   Pietersen, Alexandra M ^a,b,d  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; SOMATOMEDIN B; STAT5 PROTEIN; UNCLASSIFIED DRUG; WIP1 PROTEIN; ERBB2 PROTEIN, MOUSE; ESTROGEN; PHOSPHOPROTEIN PHOSPHATASE; PROLACTIN; PROTEIN PHOSPHATASE 2C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CONTROLLED STUDY; FEMALE; LUNG ALVEOLUS CELL; MALE; MOUSE; NONHUMAN; PARACRINE SIGNALING; PREGNANCY; ANIMAL; BREAST TUMOR; CELL TRANSFORMATION; EXPERIMENTAL MAMMARY NEOPLASM; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; UDDER;

ANIMALS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; ESTROGENS; FEMALE; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, KNOCKOUT; PHOSPHOPROTEIN PHOSPHATASES; PREGNANCY; PROLACTIN; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR;

EID: 84873024063     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3381     Document Type: Article

References (68)

1. Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, Weinberg RA. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 2007, 12:160-170. 10.1016/j.ccr.2007.06.013, 17692807.
2. Visvader JE. Cells of origin in cancer. Nature 2011, 469:314-322. 10.1038/nature09781, 21248838.
3. Garraway LA, Sellers WR. Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer 2006, 6:593-602. 10.1038/nrc1947, 16862190.
4. Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, Anderson CW, Appella E, Fornace AJ. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet 2004, 36:343-350. 10.1038/ng1317, 14991053.
5. Lambros MB, Natrajan R, Geyer FC, Lopez-Garcia MA, Dedes KJ, Savage K, Lacroix-Triki M, Jones RL, Lord CJ, Linardopoulos S, Ashworth A, Reis-Filho JS. PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. Mod Pathol 2010, 23:1334-1345. 10.1038/modpathol.2010.121, 20543821.
6. Zhu Y-H, Bulavin DV. Wip1-dependent signaling pathways in health and diseases. Prog Mol Biol Transl Sci 2012, 106:307-325.
7. Demidov ON, Kek C, Shreeram S, Timofeev O, Fornace AJ, Appella E, Bulavin DV. The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene 2007, 26:2502-2506. 10.1038/sj.onc.1210032, 17016428.
8. Brisken C, Duss S. Stem cells and the stem cell niche in the breast: an integrated hormonal and developmental perspective. Stem Cell Rev 2007, 3:147-156. 10.1007/s12015-007-0019-1, 17873347.
9. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997, 57:4987-4991.
10. Brisken C, O'Malley B. Hormone action in the mammary gland. Cold Spring Harbor Perspect Biol 2010, 2:a003178-a003178.
11. Sleeman KE, Kendrick H, Robertson D, Isacke CM, Ashworth A, Smalley MJ. Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol 2007, 176:19-26. 10.1083/jcb.200604065, 2063618, 17190790.
12. Harris J, Stanford PM, Sutherland K, Oakes SR, Naylor MJ, Robertson FG, Blazek KD, Kazlauskas M, Hilton HN, Wittlin S, Alexander WS, Lindeman GJ, Visvader JE, Ormandy CJ. Socs2 and elf5 mediate prolactin-induced mammary gland development. Mol Endocrinol 2006, 20:1177-1187. 10.1210/me.2005-0473, 16469767.
13. Visvader JE. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev 2009, 23:2563-2577. 10.1101/gad.1849509, 2779757, 19933147.
14. Oakes SR, Hilton HN, Ormandy CJ. The alveolar switch: coordinating the proliferative cues and cell fate decisions that drive the formation of lobuloalveoli from ductal epithelium. Breast Cancer Res 2006, 8:207. 10.1186/bcr1411, 1557712, 16677418.
15. Richert MM, Schwertfeger KL, Ryder JW, Anderson SM. An atlas of mouse mammary gland development. J Mammary Gland Biol Neoplasia 2000, 5:227-241. 10.1023/A:1026499523505, 11149575.
16. Ormandy CJ, Binart N, Kelly PA. Mammary gland development in prolactin receptor knockout mice. J Mammary Gland Biol Neoplasia 1997, 2:355-364. 10.1023/A:1026395229025, 10935023.
17. Wagner K-U, Krempler A, Triplett AA, Qi Y, George NM, Zhu J, Rui H. Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol Cell Biol 2004, 24:5510-5520. 10.1128/MCB.24.12.5510-5520.2004, 419899, 15169911.
18. Liu XX, Robinson GWG, Wagner KUK, Garrett LL, Wynshaw-Boris AA, Hennighausen LL. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 1997, 11:179-186. 10.1101/gad.11.2.179, 9009201.
19. Reichenstein M, Rauner G, Barash I. Conditional repression of STAT5 expression during lactation reveals its exclusive roles in mammary gland morphology, milk-protein gene expression, and neonate growth. Mol Reprod Dev 2011, 78:585-596. 10.1002/mrd.21345, 21688337.
20. Wagner K-U, Rui H. Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. J Mammary Gland Biol Neoplasia 2008, 13:93-103. 10.1007/s10911-008-9062-z, 18228120.
21. Hughes K, Watson CJ. The spectrum of STAT functions in mammary gland development. Jak-stat 2012, 1:151-158.
22. Li Y, Welm B, Podsypanina K, Huang S, Chamorro M, Zhang X, Rowlands T, Egeblad M, Cowin P, Werb Z, Tan L, Rosen J, Varmus H. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci USA 2003, 100:15853-15858. 10.1073/pnas.2136825100, 307657, 14668450.
23. Zeng YA, Nusse R. Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture. Stem Cell 2010, 6:568-577.
24. Henry MD, Triplett AA, Oh KB, Smith GH, Wagner K-U. Parity-induced mammary epithelial cells facilitate tumorigenesis in MMTV-neu transgenic mice. Oncogene 2004, 23:6980-6985. 10.1038/sj.onc.1207827, 15286714.
25. Boulanger CA, Wagner K-U, Smith GH. Parity-induced mouse mammary epithelial cells are pluripotent, self-renewing and sensitive to TGF-beta1 expression. Oncogene 2005, 24:552-560. 10.1038/sj.onc.1208185, 15580303.
26. Jeselsohn R, Brown NE, Arendt L, Klebba I, Hu MG, Kuperwasser C, Hinds PW. Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis. Cancer Cell 2010, 17:65-76. 10.1016/j.ccr.2009.11.024, 2818730, 20129248.
27. Choi J, Nannenga B, Demidov ON, Bulavin DV, Cooney A, Brayton C, Zhang Y, Mbawuike IN, Bradley A, Appella E, Donehower LA. Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control. Mol Cell Biol 2002, 22:1094-1105. 10.1128/MCB.22.4.1094-1105.2002, 134641, 11809801.
28. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988, 54:105-115.
29. Smalley MJ. Isolation, culture and analysis of mouse mammary epithelial cells. Methods Mol Biol 2010, 633:139-170. 10.1007/978-1-59745-019-5_11, 20204626.
30. Miyoshi K, Shillingford JM, Smith GH, Grimm SL, Wagner KU, Oka T, Rosen JM, Robinson GW, Hennighausen L. Signal transducer and activator of transcription (Stat) 5 controls the proliferation and differentiation of mammary alveolar epithelium. J Cell Biol 2001, 155:531-542. 10.1083/jcb.200107065, 2198867, 11706048.
31. Liu X, Robinson GW, Hennighausen L. Activation of Stat5a and Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation. Mol Endocrinol 1996, 10:1496-1506. 10.1210/me.10.12.1496, 8961260.
32. Nevalainen MT, Xie J, Bubendorf L, Wagner K-U, Rui H. Basal activation of transcription factor signal transducer and activator of transcription (Stat5) in nonpregnant mouse and human breast epithelium. Mol Endocrinol 2002, 16:1108-1124. 10.1210/me.16.5.1108, 11981045.
33. Larsen CM, Grattan DR. Prolactin-induced mitogenesis in the subventricular zone of the maternal brain during early pregnancy is essential for normal postpartum behavioral responses in the mother. Endocrinology 2010, 151:3805-3814. 10.1210/en.2009-1385, 20484459.
34. Oakes SR, Naylor MJ, Asselin-Labat M-L, Blazek KD, Gardiner-Garden M, Hilton HN, Kazlauskas M, Pritchard MA, Chodosh LA, Pfeffer PL, Lindeman GJ, Visvader JE, Ormandy CJ. The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes Dev 2008, 22:581-586. 10.1101/gad.1614608, 2259028, 18316476.
35. Haslam SZ, Shyamala G. Effect of oestradiol on progesterone receptors in normal mammary glands and its relationship with lactation. Biochem J 1979, 182:127-131. 1161241, 496902.
36. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000, 103:41-50. 10.1016/S0092-8674(00)00103-3, 11051546.
37. Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, Schneider P, Brisken C. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA 2010, 107:2989-2994. 10.1073/pnas.0915148107, 2840294, 20133621.
38. Brisken C, Ayyannan A, Nguyen C, Heineman A, Reinhardt F, Tan J, Dey SK, Dotto GP, Weinberg RA, Jan T. IGF-2 is a mediator of prolactin-induced morphogenesis in the breast. Dev Cell 2002, 3:877-887. 10.1016/S1534-5807(02)00365-9, 12479812.
39. Santos SJ, Haslam SZ, Conrad SE. Signal transducer and activator of transcription 5a mediates mammary ductal branching and proliferation in the nulliparous mouse. Endocrinology 2010, 151:2876-2876. 10.1210/en.2009-1282, 2875824, 20392833.
40. Srivastava S, Matsuda M, Hou Z, Bailey JP, Kitazawa R, Herbst MP, Horseman ND. Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. J Biol Chem 2003, 278:46171-46178. 10.1074/jbc.M308545200, 12952963.
41. Lee HJ, Ormandy CJ. Interplay between progesterone and prolactin in mammary development and implications for breast cancer. Mol Cell Endocrinol 2012, 357:101-107. 10.1016/j.mce.2011.09.020, 21945475.
42. Hovey RCR, Harris JJ, Hadsell DLD, Lee AVA, Ormandy CJC, Vonderhaar BKB. Local insulin-like growth factor-II mediates prolactin-induced mammary gland development. Mol Endocrinol 2003, 17:460-471. 10.1210/me.2002-0214, 12554791.
43. Furth PA, Nakles RE, Millman S, Díaz-Cruz ES, Cabrera MC. Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer. Breast Cancer Res 2011, 13:220-220. 10.1186/bcr2921, 3262193, 22018398.
44. Hovey RCR, Trott JFJ, Ginsburg EE, Goldhar AA, Sasaki MMM, Fountain SJS, Sundararajan KK, Vonderhaar BKB. Transcriptional and spatiotemporal regulation of prolactin receptor mRNA and cooperativity with progesterone receptor function during ductal branch growth in the mammary gland. Dev Dyn 2001, 222:192-205. 10.1002/dvdy.1179, 11668597.
45. Grimm SL, Seagroves TN, Kabotyanski EB, Hovey RC, Vonderhaar BK, Lydon JP, Miyoshi K, Hennighausen L, Ormandy CJ, Lee AV, Stull MA, Wood TL, Rosen JM. Disruption of steroid and prolactin receptor patterning in the mammary gland correlates with a block in lobuloalveolar development. Mol Endocrinol 2002, 16:2675-2691. 10.1210/me.2002-0239, 12456789.
46. Santos SJ, Haslam SZ, Conrad SE. Estrogen and progesterone are critical regulators of Stat5a expression in the mouse mammary gland. Endocrinology 2007, 149:329-338. 10.1210/en.2007-0594, 2194608, 17884938.
47. Ahmed ST, Mayer A, Ji J-D, Ivashkiv LB. Inhibition of IL-6 signaling by a p38-dependent pathway occurs in the absence of new protein synthesis. J Leukoc Biol 2002, 72:154-162.
48. Faulds MHM, Pettersson KK, Gustafsson JAJ, Haldosén LAL. Cross-talk between ERs and signal transducer and activator of transcription 5 is E2 dependent and involves two functionally separate mechanisms. Mol Endocrinol 2001, 15:1929-1940. 10.1210/me.15.11.1929, 11682624.
49. Buser AC, Obr AE, Kabotyanski EB, Grimm SL, Rosen JM, Edwards DP. Progesterone receptor directly inhibits β-casein gene transcription in mammary epithelial cells through promoting promoter and enhancer repressive chromatin modifications. Mol Endocrinol 2011, 25:955-968. 10.1210/me.2011-0064, 3386529, 21527503.
50. Viengchareun S, Servel N, Fève B, Freemark M, Lombès M, Binart N. Prolactin receptor signaling is essential for perinatal brown adipocyte function: a role for insulin-like growth factor-2. PLoS ONE 2008, 3:e1535. 10.1371/journal.pone.0001535, 2212135, 18253483.
51. Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci USA 2003, 100:9744-9749. 10.1073/pnas.1732707100, 187836, 12897242.
52. Proia DA, Nannenga BW, Donehower LA, Weigel NL. Dual roles for the phosphatase PPM1D in regulating progesterone receptor function. J Biol Chem 2006, 281:7089-7101. 10.1074/jbc.M511839200, 16352595.
53. Mukherjee A, Soyal SM, Li J, Ying Y, He B, DeMayo FJ, Lydon JP. Targeting RANKL to a specific subset of murine mammary epithelial cells induces ordered branching morphogenesis and alveologenesis in the absence of progesterone receptor expression. FASEB J 2010, 24:4408-4419. 10.1096/fj.10-157982, 2974417, 20605949.
54. Ménard S, Aiello P, Tagliabue E, Rumio C, Lollini PL, Colnaghi MI, Balsari A. Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model. Cancer Res 2000, 60:273-275.
55. Medina DD, Kittrell FSF, Hill JJ, Shepard AA, Thordarson GG, Brown PP. Tamoxifen inhibition of estrogen receptor-alpha-negative mouse mammary tumorigenesis. Cancer Res 2005, 65:3493-3496.
56. Das R, Vonderhaar BK. Tamoxifen inhibits prolactin signal transduction in ER - NOG-8 mammary epithelial cells. Cancer Lett 1997, 116:41-46. 10.1016/S0304-3835(97)04750-2, 9177456.
57. Oakes SRS, Robertson FGF, Kench JGJ, Gardiner-Garden MM, Wand MPM, Green JEJ, Ormandy CJC. Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oncogene 2007, 26:543-553. 10.1038/sj.onc.1209838, 16862169.
58. Sakamoto K, Lin WC, Triplett AA, Wagner KU. Targeting janus kinase 2 in her2/neu-expressing mammary cancer: implications for cancer prevention and therapy. Cancer Res 2009, 69:6642-6650. 10.1158/0008-5472.CAN-09-0746, 2758773, 19638583.
59. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010, 468:103-107. 10.1038/nature09495, 20881963.
60. Wagner KU, McAllister K, Ward T, Davis B, Wiseman R, Hennighausen L. Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgen Res 2001, 10:545-553.
61. Andrechek ER, Laing MA, Girgis-Gabardo AA, Siegel PM, Cardiff RD, Muller WJ. Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. Cancer Res 2003, 63:4920-4926.
62. Purdie CA, Baker L, Ashfield A, Chatterjee S, Jordan LB, Quinlan P, Adamson DJA, Dewar JA, Thompson AM. Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study. Br J Cancer 2010, 103:475-481. 10.1038/sj.bjc.6605799, 2939790, 20664587.
63. Tworoger SS, Hankinson SE. Prolactin and breast cancer etiology: an epidemiologic perspective. J Mammary Gland Biol Neoplasia 2008, 13:41-53. 10.1007/s10911-008-9063-y, 18246319.
64. Medina D, Kittrell FS, Shepard A, Contreras A, Rosen JM, Lydon J. Hormone dependence in premalignant mammary progression. Cancer Res 2003, 63:1067-1072.
65. Mazumdar A, Medina D, Kittrell FS, Zhang Y, Hill JL, Edwards D, Bissonnette RP, Brown P. The combination of tamoxifen and the rexinoid LG100268 prevents ER-positive and ER-negative mammary tumors in P53-null mammary gland mice. Cancer Prev Res (Phila) 2012, 5:1195-1202.
66. Yagi H, Chuman Y, Kozakai Y, Imagawa T, Takahashi Y, Yoshimura F, Tanino K, Sakaguchi K. A small molecule inhibitor of p53-inducible protein phosphatase PPM1D. Bioorg Med Chem Lett 2012, 22:729-732. 10.1016/j.bmcl.2011.10.084, 22115592.
67. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, Moreno-Bueno G, Tan DSP, Marchio C, Vatcheva R, Rayter S, Mahler-Araujo B, Fulford LG, Hungermann D, Mackay A, Grigoriadis A, Fenwick K, Tamber N, Hardisson D, Tutt A, Palacios J, Lord CJ, Buerger H, Ashworth A, Reis-Filho JS. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009, 15:2711-2722. 10.1158/1078-0432.CCR-08-1878, 19318498.
68. Howell A, Bundred NJ, Cuzick J, Allred DC, Clarke R. Response and resistance to the endocrine prevention of breast cancer. Adv Exp Med Biol 2008, 617:201-211. 10.1007/978-0-387-69080-3_19, 18497044.